Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Consensus Rating of “Moderate Buy” by Brokerages

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) has received an average rating of “Moderate Buy” from the seven analysts that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $13.80.

Several equities analysts have recently commented on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Orchestra BioMed in a research report on Wednesday, October 8th. TD Cowen started coverage on shares of Orchestra BioMed in a research note on Wednesday, December 10th. They issued a “buy” rating on the stock. Chardan Capital restated a “buy” rating and set a $20.00 price objective on shares of Orchestra BioMed in a research report on Thursday, November 13th. Finally, Barclays raised their target price on Orchestra BioMed from $11.00 to $12.00 and gave the company an “overweight” rating in a report on Friday, January 9th.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of OBIO. AMH Equity Ltd acquired a new position in Orchestra BioMed during the 3rd quarter worth approximately $412,000. Knott David M Jr acquired a new stake in Orchestra BioMed in the second quarter valued at approximately $268,000. Catalyst Funds Management Pty Ltd bought a new stake in shares of Orchestra BioMed during the second quarter worth $31,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Orchestra BioMed during the second quarter worth $122,000. Finally, Creative Planning acquired a new position in shares of Orchestra BioMed during the second quarter worth $40,000. Institutional investors and hedge funds own 53.20% of the company’s stock.

Orchestra BioMed Stock Performance

OBIO opened at $4.08 on Wednesday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 4.72 and a current ratio of 4.73. Orchestra BioMed has a 52-week low of $2.20 and a 52-week high of $6.16. The firm has a market cap of $230.40 million, a P/E ratio of -2.24 and a beta of 0.61. The business’s fifty day moving average is $4.38 and its 200-day moving average is $3.59.

Orchestra BioMed (NASDAQ:OBIO) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). The company had revenue of $0.86 million during the quarter, compared to analyst estimates of $0.74 million. Orchestra BioMed had a negative net margin of 2,665.05% and a negative return on equity of 320.09%. Sell-side analysts expect that Orchestra BioMed will post -1.66 EPS for the current fiscal year.

About Orchestra BioMed

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.